Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.83 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.74 |
| ▸ | CRHBP | P24387 | 1/20 | 0.69 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | XDH | P47989 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731374 | 0.91 | MPO (1.00) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL2731155 | 0.85 | MPO (1.00) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL12713432 | 0.83 | MPO (0.73) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL2731546 | 0.80 | MPO (1.00) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL6299962 | 0.80 | CYP1A2 (0.71) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL2723795 | 0.79 | MPO (0.92) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL10289181 | 0.79 | MPO (0.63) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL2730381 | 0.78 | MPO (0.90) | MPOHAVCR2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL7648079 | 0.75 | ALDH1A1 (0.74) | MPOHAVCR2ALDH1A1XDHSMN1; SMN2 | |
| SCHEMBL29446470 | 0.75 | NPC1 (1.00) | MPOHAVCR2CRHBPCRHR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632466-A2 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | Emory University (US) | 2013-09-04 | — | — | EP | claimed |
| US-20130225612-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | claimed |
| WO-2012058211-A2 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2012-05-03 | — | — | WO | claimed |
| US-9868728-B2 | Quinazoline derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2886120-A1 | Quinazoline derivatives, compositions and uses related thereto | Emory University (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20130225612-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225612-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225612-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | NOX4, NOX5, NQO2 | MPO 10/4885HAVCR2 4569/4885CRHBP 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.